Skip to main content

Table 6 Health outcomes and economic impact of PHiD-CV vs. PCV13 vaccination programs

From: Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan

  PCV13 (A) PHiD-CV (B) Difference (B−A)
Health outcomes
 IPD cases (acute episode) 99 108 9
 All-cause pneumonia cases (acute episode) 19,714 19,754 40
 AOM cases (acute episode) 135,206 130,783 −4424
 Deaths due to IPD/pneumonia 17 17 0
Costs
 Vaccination NTD 926 465 468 NTD 926 465 418 − NTD 50
 Acute episode
  IPD NTD 7 341 171 NTD 7 992 670 NTD 651 499
  All-cause pneumonia NTD 352 720 474 NTD 353 278 362 NTD 557 957
  AOM NTD 189 117 177 NTD 178 291 679 − NTD 10 825 498
 Total
  Undiscounted NTD 1 475 644 291 NTD 1 466 028 130 - NTD 9 616 161
  Discounted NTD 1 392 017 676 NTD 1 383 217 323 - NTD 8 800 353
  1. AOM acute otitis media, IPD invasive pneumococcal disease, PCV13 13-valent pneumococcal conjugate vaccine, PHiD-CV 10-valent pneumococcal polysaccharide and NTHi protein D conjugate vaccine, NTD new Taiwan dollar
\